Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + tremelimumab with personalized or standard SIRT versus immunotherapy with on-demand SIRT in non-resectable hepatocellular carcinoma
2024-515127-11-00Phase 2Authorised
- Sponsor
- LMU Klinikum
- Start
- Aug 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of durvalumab and tremelimumab in hepatocellular carcinoma (HCC) (3 arms), sponsored by LMU Klinikum. Primary endpoint: Objective response rate. Planned start Aug 2024; status: authorised.
02
Drugs
durvalumabtremelimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2024-515127-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515127-11-00.